TY - JOUR
T1 - Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies
AU - Minocha, Rashi
AU - Kefford, Richard
AU - Uribe, Pablo
AU - Sebaratnam, Deshan F.
AU - Fernández-Peñas, Pablo
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Diffuse melanosis cutis (DMC) is a rare presentation of metastatic melanoma associated with a particularly guarded prognosis. We report a case of a 35-year-old man with BRAFV600E metastatic melanoma treated with dabrafenib (as well as ipilimumab and whole brain radiotherapy), who is alive, 25 months after the onset of his DMC. This is significantly longer than the reported mean survival of 4 months, highlighting the importance of BRAF mutation testing and the promising survival advantage of using targeted therapies compared with conventional chemotherapeutic regimens.
AB - Diffuse melanosis cutis (DMC) is a rare presentation of metastatic melanoma associated with a particularly guarded prognosis. We report a case of a 35-year-old man with BRAFV600E metastatic melanoma treated with dabrafenib (as well as ipilimumab and whole brain radiotherapy), who is alive, 25 months after the onset of his DMC. This is significantly longer than the reported mean survival of 4 months, highlighting the importance of BRAF mutation testing and the promising survival advantage of using targeted therapies compared with conventional chemotherapeutic regimens.
UR - http://www.scopus.com/inward/record.url?scp=84928152912&partnerID=8YFLogxK
U2 - 10.1111/ajd.12187
DO - 10.1111/ajd.12187
M3 - Article
C2 - 25159853
AN - SCOPUS:84928152912
SN - 0004-8380
VL - 56
SP - 128
EP - 130
JO - Australasian Journal of Dermatology
JF - Australasian Journal of Dermatology
IS - 2
ER -